Technology
Health
Pharmaceutical

Novan

$1.37
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (3.79%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Novan and other stocks, options, ETFs, and crypto commission-free!

About

Novan, Inc. Common Stock, also called Novan, is a biotechnology company which uses nitric oxide-based technology to develop product candidates. Read More It focuses on nitric oxide's natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Morrisville, NC.

Employees
59
Headquarters
Morrisville, North Carolina
Founded
2006
Market Cap
34.39M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
52.04K
High Today
$1.40
Low Today
$1.32
Open Price
$1.33
Volume
75.34K
52 Week High
$3.47
52 Week Low
$0.652

Collections

Technology
Health
Pharmaceutical
Biotechnology
Medical
2016 IPO
US
North America

News

Associated PressMar 19

Novan and Sato Advance Japan Market and Dermatology Partnership

-- Dr. Elizabeth Messersmith named chairperson of the Sato and Novan Joint Committee -- Simultaneous clinical development progress for SB206 in Japan and US underway -- Novan receives second installment of $4.5 million under the SB206 Japan license agreement MORRISVILLE, N.C., March 19, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that the Company has named Dr. Elizabeth Messersmith, the Company’s Senior Vice President and Chief Development Officer, the chai...

59
MarketBeatFeb 27

VTX:NOVN - Stock Price, News, & Analysis for Novartis

Novan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for t...

11
PR NewswireFeb 26

KNOW Bio Announces Creation of Digestive Health Therapeutics, Inc.

DURHAM, N.C., Feb. 26, 2019 /PRNewswire/ -- KNOW Bio, LLC., (the Company), a North Carolina developer of nitric oxide-based medical technology and related biotechnology companies, announced today that the Company has formed a new wholly-owned operating subsidiary, Digestive Health Therapeutics, Inc, to develop the Company's technology in the field of gastroenterology. Dr. Mark Schoenfisch, inventor of the enabling technology and KNOW Bio Director stated, "Nitric oxide is a cellular messenger with important...

45

Earnings

-$0.62
-$0.48
-$0.35
-$0.21
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.31 per share
Actual
Expected Mar 27, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.